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Abstract The objective of this article is to determine
whether racial/ethnic disparities exist in screening for
group B streptococcus (GBS) colonization among pregnant
women. A retrospective cohort study of deliveries at a
single institution was conducted. The primary outcome was
the availability of GBS culture data at the time of delivery;
the primary predictor was maternal race/ethnicity. Analy-
ses were stratiﬁed by the time periods before and after the
CDC recommendations for universal screening for GBS.
Among 16,333 deliveries, 60.4% of the population was
screened for GBS but screening rates varied markedly by
year of delivery. Black women had a lower odds of having
available GBS data (AOR 0.81 [0.69, 0.95]) but this dis-
parity was limited to the period of time before universal
screening was recommended. Prior to the recommendation
for universal screening for GBS, racial/ethnic disparities
existed in rates of screening among pregnant women
delivering at term. These differences were reduced after
2002, suggesting that uniform policies regarding obstetrical
care may be effective in eliminating disparities in obstet-
rical care and outcomes.
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Introduction
Wide disparities in health outcomes have been described
for racial and ethnic minorities in the United States. The
Institute of Medicine, charged with examining disparate
health outcomes, found that a large body of research sup-
ports inequities in health care as possible contributors to
inequities in health [1]. Though disparities in obstetrical
outcomes have been well documented [2–4], differential
obstetrical care by maternal race/ethnicity has been less
well studied [5].
The prevention of early onset group B streptococcal
(GBS) infection in neonates has become a major public
health effort. The 1990s saw a signiﬁcant decline in cases
of early GBS disease, from 2 to 3 cases per 1,000 live
births to 0.5 cases per 1,000 live births, thought largely due
to more widespread use of intrapartum antibiotic prophy-
laxis (IAP) [6, 7]. In 1996, the Centers for Disease Control
and Prevention (CDC) issued guidelines for the prevention
of perinatal GBS disease, and allowed obstetrical providers
to choose between two strategies for maternal risk strati-
ﬁcation [8]. In one (risk factor-based), women presenting in
labor were evaluated for risk factors for early onset GBS
disease (preterm gestation, fever in labor, prolonged rup-
ture of membranes, for example) and treated if criteria for
risk were met. In the other strategy (screening-based),
recto-vaginal cultures for GBS were collected between 35
and 37 weeks gestation, and women with positive cultures
were treated with IAP in labor. In 2002, the CDC released
new guidelines, reﬂective of surveillance data collected
since the 1996 release, which compared the effectiveness
of the two screening strategies [9]. The new recommen-
dations included guidelines for universal GBS screening,
with the risk-factor based approach deemed to be a sub-
standard strategy.
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GBS screening would provide evidence of inconsistencies
in the quality of care delivered to obstetrical patients and
would serve as a concrete area for quality improvement
efforts on the part of health care providers and systems.
The documentation of such inequities generally provides a
ﬁrst step towards ameliorating them. To date, few metrics
of quality of obstetric care have been identiﬁed and used to
assess quality, equality or adequacy of care. The ﬁnding of
disparities in a process of care measure such as GBS
screening may be causally related to disparities in neonatal
outcomes. In the current study, we sought to test our
hypothesis that racial and ethnic minority women, in par-
ticular, Black women, would be less likely to be screened
for GBS than White women, both during the time period in
which screening or risk-factor based strategies were
endorsed by CDC (1996–2002), as well as during the
period of recommendation for universal screening (2002
and beyond). We also tested the hypothesis that disparities
by race/ethnicity would exist irrespective of insurance
status (i.e., publicly vs. privately insured), and that among
those women screened, rates of GBS carriage were higher
among Black women, in particular.
Materials and Methods
We conducted a retrospective cohort study of women
delivering at the University of California, San Francisco
(UCSF) between 1996 and 2008. The primary outcome for
this study was availability of a recto-vaginal GBS culture
result at delivery as a measure of having had screening for
GBS performed; the primary predictor was self-reported
maternal race/ethnicity. In addition, data on maternal socio-
demographic and clinical characteristics were evaluated
as covariates. The UCSF Department of Obstetrics, Gyne-
cology & Reproductive Sciences maintains a perinatal
database of all deliveries occurring at UCSF Mofﬁtt-Long
Hospital. This is a prospectively collected, research-quality
obstetric database. Each woman’s prenatal and inpatient
medical record is abstracted by trained research personnel
and entered into this database.
Women who delivered at or beyond 37 completed weeks
of gestation were included in these analyses, as recom-
mendations for the screening strategy call for cultures to be
conducted between 35 and 37 weeks of pregnancy. Women
transported to our institution for delivery were excluded
from analyses, as were women with no information on
maternal race/ethnicity. We conducted bivariate analyses,
using chi-squared tests, t-tests and logistic regression to
assess the association between availability of GBS culture
and each maternal race/ethnicity category, as well as for
several other potential confounding factors such as
maternal age, parity, number of prenatal care visits, history
of a preterm delivery and insurance status. Those variables
that were found to be statistically signiﬁcantly associated
(at the P\0.10 level) with availability of GBS culture
were retained in multivariable logistic regression models
which predicted GBS culture availability as a function of
maternal race/ethnicity. These models were also adjusted
for gestational age at delivery and year of delivery. We
stratiﬁed analyses by time period (1996–2001 and
2002–2008), and also included a test for trend by year of
delivery. We tested our hypothesis that disparities in GBS
screening are not modiﬁed by maternal insurance status by
testing an interaction between race/ethnicity and insurance
status.
To demonstrate consistency with ﬁndings in other pop-
ulations, we sought to conﬁrm that rates of GBS carriage
are higher among racial and ethnic minorities in our pop-
ulation by creating multivariable logistic models of GBS
carriage among women for whom culture data were
available. All analyses were conducted using the Stata 9
statistical package (StataCorp, College Station, TX). This
study received institutional approval from the Committee
on Human Research at the University of California, San
Francisco.
Results
After exclusion of 603 women with missing data on race/
ethnicity, there were 16,333 women who met study inclu-
sion criteria. Overall, GBS culture data were present at
delivery in 60.4% of all patients. This varied greatly by
year of delivery: for those women delivering between 1996
and 2001 (before the CDC recommendation for universal
screening), the proportion of available cultures was 26.9%.
Between 2002 and 2008, the proportion of available culture
data was 86.2%. In 2008, the proportion was 98.5%.
Characteristics of the study population are shown in
Table 1. In unadjusted analyses, Asian (odds ratio (OR)
0.86 [95% CI 0.80, 0.94]) and Black women OR 0.73
[0.66, 0.80] were less likely to have GBS results available
than were white women. Known GBS status at delivery
was also associated with older maternal age and private
insurance. In multivariable regression modeling, also pre-
sented in Table 1, Black race remained an independent
predictor of absence of a GBS result at delivery (adjusted
odd ratio (AOR) 0.80 [0.69, 0.94]). Models were adjusted
for parity, public vs. private insurance, number of prenatal
visits, gestational age, prior preterm delivery, and year of
delivery.
When we stratiﬁed the population by year of delivery
(1996–2001 vs. 2002–2008; Table 2), Black women
remained statistically signiﬁcantly at lower odds of having
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123GBS culture data available at delivery in the earlier time
period (AOR 0.79 [0.65, 0.97]) but this lower odds did not
reach statistical signiﬁcance in the later time period (AOR
0.85 [0.65, 1.12]). During 1996–2001, Asian women were
also less likely to have known GBS status (AOR 0.75
[0.63, 0.88]), but not during 2002–2008. In the earlier time
period public health insurance coverage was associated
with a lower odds of GBS status availability (AOR 0.83
[0.71, 0.98]), but not in the later time period. No signiﬁcant
interactions were noted between race/ethnicity and insur-
ance status during either time period.
A test for trend shows a signiﬁcant increase in the odds
of available GBS data at delivery in more recent years
(P\0.001). Relative to the year 2002, the odds of having
a GBS culture available in 1996 was 0.61 [0.51, 0.73], and
was 140.3 [76.2, 258.5] in 2008. Figure 1 demonstrates the
proportion of women with available GBS data by race/
ethnicity and year of delivery. Prior to 2002, women of
racial/ethnic minorities were less likely, on average, to
have GBS screening completed by delivery, while after
2002, the differences are less pronounced.
When we explored the rates of GBS-positive culture
among women with culture data available at delivery,
women of all minority groups were more likely to have
GBS detected on rectovaginal culture than were white
women (AOR for Asians 1.22 [1.07, 1.40], Blacks 1.98
[1.68, 2.35], Latinas 1.32 [1.13, 1.55] and other 1.31 [1.12,
1.53]; Table 3).
Comment
In our population of women with term deliveries, Black
women were signiﬁcantly less likely to be screened for
GBS than were White women. These ﬁndings were most
signiﬁcant during the time period when the CDC allowed
for a risk-factor based or screening-based approach to the
reduction of early-onset GBS disease (EOD). Following
their 2002 recommendations for universal screening for
GBS, rates of screening were similar for women of dif-
ferent race/ethnicities. During the same time period, there
was a dramatic increase in overall screening rates for GBS,
as has been documented elsewhere [10].
Disparities in recommended screening for GBS are of
concern, especially in light of the recent release of sur-
veillance data for EOD in the United States between 2000
and 2006. It is well known that Black race is a risk factor
for EOD [6, 11, 12]. The most recent data demonstrate that
the sole group in which the incidence of EOD is on the rise
is Black term infants, a group which saw an increase in
incidence from 0.33 cases per 1,000 live births to 0.70
cases per 1,000 live births from 2003 to 2006 [13]. Ineq-
uities in quality of care may contribute to inequities in
neonatal outcomes.
A prior study in North Carolina in 2002–2003 showed
that Hispanic women and women receiving care in a hos-
pital clinic or health department were less likely to be
screened for GBS [14]. This study relied on maternal self-
report; our study has as a strength our ability to have
objective evidence of GBS status availability. Another
investigation of predictors of screening for perinatal infec-
tionsin2000–2001revealednodifferencesbyrace/ethnicity
or insurance status with regards to universally-recom-
mended screenings for infections such as hepatitis B,
syphilis and rubella, but did show some variation by both
race/ethnicity and insurance for infections in which rec-
ommendationsatthetimewerebasedonriskfactors,suchas
GBS,hepatitisCandvaricella[15].Theauthors suggestthat
the systems of care in which minority and poor women may
be enrolled may have different practice standards, reﬂective
of provider and patient awareness, as well as reimbursement
rates of insurers. Our ﬁnding that race/ethnicity and insur-
ance predicted GBS screening in the era prior to the rec-
ommendation for universal screening, but not after, would
support this notion. The institution of uniform practice
standards and the reduction in permissive variability in care
may be effective strategies to reduce disparities in health
care and outcomes. We also conﬁrm a higher risk among
Black women of carriage of GBS among those women who
Table 1 Socio-demographic and clinical characteristics of the study
population, N = 16,333
% population
or (mean ± SD)
% with
available GBS
culture or
(mean ± SD)
P
Race/ethnicity \0.001
Asian 17.3 58.9
Black 12.8 54.8
Latina 11.4 62.1
White 45.9 62.4
Other 12.6 59.0
Age (30.2 ± 6.2) (30.7 ± 6.1) \0.001
Parity 0.07
Nulliparous 54.9 61.0
Multiparous 45.1 59.6
Insurance \0.001
Private 75.6 62.0
Public 24.4 55.3
Number of visits (7.9 ± 3.2) (7.5 ± 3.2) \0.001
Previous preterm delivery 2.1 50.3 \0.001
Year of delivery \0.001
1996–2001 43.5 26.9
2002–2008 56.5 86.2
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123were screened during pregnancy, consistent with other
reports [16, 17], and reiterating the need for adherence to
best practices for screening in all populations.
Our study beneﬁts from its conduct in a single delivery
center and from inclusion only of patients with term
deliveries, not transported to our institution from other
centers. We therefore believe that our ascertainment of
availability of GBS data is quite good, though we are not
able to validate the accuracy of the perinatal database using
primary microbiology laboratory records. While there is a
possibility of differential documentation of GBS status in
the medical chart by race/ethnicity or practice, we believe
this to be minimal. Our ability to capture deliveries from
the entire period from the 1996 CDC recommendations for
Table 2 Unadjusted and adjusted odds of available GBS culture, in all years and stratiﬁed by year of delivery
Unadjusted OR for
available GBS
culture (95% CI):
all years
Adjusted OR
a for
available GBS
culture (95% CI):
all years
Unadjusted OR for
available GBS
culture (95% CI):
1996–2001
Adjusted OR
a for
available GBS
culture (95% CI):
1996–2001
Unadjusted OR for
available GBS
culture (95% CI):
2002–2008
Adjusted OR
a for
available GBS
culture (95% CI):
2002–2008
Race/ethnicity
Asian 0.86 (0.80,0.94) 0.89 (0.78, 1.01) 0.79 (0.68, 0.92) 0.75 (0.63 0.88) 1.09 (0.92, 1.30) 1.18 (0.95, 1.47)
Black 0.73 (0.66,0.80) 0.81 (0.69, 0.95) 0.77 (0.65, 0.91) 0.79 (0.65, 0.97) 0.86 (0.72, 1.04) 0.85 (0.65, 1.12)
Latina 0.98 (0.89,1.09) 0.92 (0.78, 1.08) 1.01 (0.85, 1.21) 1.01 (0.83, 1.22) 1.10 (0.92, 1.30) 0.80 (0.61 1.03)
White 1.00 1.00 1.00 1.00 1.00 1.00
Other 0.86 (0.78,0.95) 0.88 (0.76, 1.02) 0.84 (0.71, 1.00) 0.80 (0.66, 0.96) 1.16 (0.95, 1.42) 1.05 (0.81, 1.36)
Age 1.03 (1.02,1.03) 1.00 (0.99, 1.01) 1.01 (1.00, 1.01) 1.00 (0.99, 1.01) 1.01 (1.00, 1.02) 0.99 (0.98, 1.00)
Parity
Nulliparous 1.06 (1.00,1.12) See footnote 0.95 (0.86, 1.06) See footnote 1.28 (1.14, 1.44) See footnote
Multiparous 1.00 1.00 1.00
Insurance
Private 1.00 1.00 1.00 1.00 1.00 1.00
Public 0.75 (0.71,0.82) 0.87 (0.77, 0.99) 0.86 (0.77, 0.97) 0.83 (0.71, 0.98) 0.93 (0.81, 1.08) 0.92 (0.74, 1.13)
Number of
visits
0.91 (0.90,0.92) See footnote 0.98 (0.97, 1.00) See footnote 1.04 (1.02, 1.06) See footnote
Previous
preterm
delivery
0.69 (0.53,0.82) 1.45 (1.09, 1.94) 1.44 (1.09, 1.92) 1.50 (1.10, 2.04) 0.62 (0.40, 0.98) 0.72 (0.40, 1.30)
Year of delivery
1996–2001 1.00 See footnote
2002–2008 16.9 (15.6,18.3)
a Adjusted for other covariates presented, in addition to parity (as a continuous variable), gestational age, number of prenatal visits (as a
categorical variable) and year of delivery
Values in italics have P\0.05
Availability of GBS culture data at delivery (%)
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Fig. 1 Proportion of women with available GBS culture data, by
year of delivery and maternal race/ethnicity
Table 3 Risk of presence of GBS on rectovaginal culture by race/
ethnicity, among women with known GBS status
Race/ethnicity GBS?/number screened (%) Adjusted OR
a
Asian 415/1,733 (24.1) 1.22 (1.07, 1.40)
Black 432/1,192 (36.2) 1.98 (1.68, 2.35)
Latina 321/1,201 (26.7) 1.32 (1.13, 1.55)
White 990/4,836 (20.5) 1.00
Other 311/1,255 (24.8) 1.31 (1.12, 1.53)
a Adjusted for maternal age, parity, gestational age, number of pre-
natal visits, insurance, year of delivery and prior preterm delivery
Values in italics have P\0.05
Matern Child Health J (2011) 15:1160–1165 1163
123screening vs. risk factor based protocols, through their
mandate for universal screening and into the present day
also represents a strength. We do not believe the associa-
tion between race/ethnicity and availability of GBS results
to be confounded by the natures of the practices in which
patients are seen; in our institution, insurance status is a
close proxy for obstetrical practice, and we have adjusted
for the former in our analyses.
Our study is not without limitations, however. Our
outcome is derived from review of the medical record, and
not from laboratory data. While in some ways this limits
our ability to comment on ‘‘true availability’’ of culture
data, our outcome deﬁnition lies closest to the information
available to the providers at the time prenatal and intra-
partum care was rendered. Other studies have documented
that, despite high rates of overall screening since 2002,
screening may not occur at the appropriate time (e.g., prior
to 35 weeks, then not repeated) [18, 19]; we did not look
speciﬁcally at this phenomenon. We are also unable to
comment on rates on intrapartum antibiotic prophylaxis
among women with risk factors or positive screens for GBS
in this population; this rate represents another potential
measure of obstetrical care quality. And lastly, while it is
likely that Black women in this population were somewhat
more likely to have had GBS bacteriuria or a prior neonate
affected by invasive GBS disease, and thus appropriately
not screened by recto-vaginal culture in the index preg-
nancy, we do not believe that the magnitude of the racial/
ethnic differences in these conditions explains the extent of
the absolute difference in screening rates that we witnessed
in the early period.
Disparities in quality of care exist throughout health
care. Racial and ethnic minorities are less likely to receive
recommended immunizations, less likely to be screened for
colorectal cancer and less likely to receive weight man-
agement counseling if obese [20]. It is therefore not sur-
prising that disparities in quality of obstetrical care exist as
well. In our ﬁeld, however, we have relatively few agreed-
upon metrics of quality care [21]. Screening for GBS,
while not a measure used by groups such as the Agency for
Healthcare Research and Quality when reporting quality of
care, is clearly a key component of antenatal care, with
relevance to neonatal outcomes. Disparities in this proce-
dure should raise a warning that similar disparities likely
exist in other areas of obstetric care that allow for similar
variability in management styles as seen in the pre-2002
era of GBS screening. While other process measures are
perhaps less easily measured, they may be no less impor-
tant to maternal and infant outcomes. Increasing awareness
of obstetrical disparities will hopefully serve to eliminate
them. Clinical, research and health policy endeavors should
have as a goal ensuring that patients, providers and systems
of care all contribute positively to equitable processes of
care and health outcomes.
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